Liangjun Yang1, Zhipeng Hu2, Jiajie Zhu1, Baoying Fei1,3. 1. Department of Gastroenterology, Tongde Hospital of Zhejiang Province. 2. Hospital of Chengdu University of Traditional Chinese Medicine, Sichuan Province. 3. Digestive Disease Institute of Integrated Traditional Chinese and Western Medicine, Zhejiang Academy of Traditional Chinese Medicine, Zhejiang Province, China.
Abstract
BACKGROUND: Chronic atrophic gastritis (CAG) is defined as an important precancerous disease in the development of gastric cancer. Early intervention of CAG is of great significance in reducing symptoms and blocking its progression to gastric cancer. Weifuchun (WFC) tablet is a classic Chinese patent medicine used to treat CAG. However, there is no systematic review related to WFC for atrophic gastritis published in English. we will conduct systematic review and meta-analysis to provide more evidence on the effectiveness and safety for clinical use of WFC. METHODS AND ANALYSIS: Three English database and 4 Chinese databases will be searched from its inception to April 2020. Two trained researchers will independently select the qualified studies for data extraction and assess the quality and risk of bias. Then the meta-analyses will be performed by using the RevMan 5.2 and stata 14.0. The heterogeneity of data will be investigated by Cochrane X and I tests. Sensitivity analysis will be conducted to evaluate the stability of the results. A funnel plot analysis and Egger's test will be drawn to assess the publication bias. Finally, we will use the Grading of Recommendations Assessment, Development and Evaluate system to evaluate the methodological quality. RESULTS: The results of our research will be published in a peer-reviewed journal. CONCLUSION: The conclusion of our systematic review will provide evidence to judge whether WFC is an effective intervention for patient with CAG. OSF REGISTRATION NUMBER: 10.17605/OSF.IO/2UTMB.
BACKGROUND: Chronic atrophic gastritis (CAG) is defined as an important precancerous disease in the development of gastric cancer. Early intervention of CAG is of great significance in reducing symptoms and blocking its progression to gastric cancer. Weifuchun (WFC) tablet is a classic Chinese patent medicine used to treat CAG. However, there is no systematic review related to WFC for atrophic gastritis published in English. we will conduct systematic review and meta-analysis to provide more evidence on the effectiveness and safety for clinical use of WFC. METHODS AND ANALYSIS: Three English database and 4 Chinese databases will be searched from its inception to April 2020. Two trained researchers will independently select the qualified studies for data extraction and assess the quality and risk of bias. Then the meta-analyses will be performed by using the RevMan 5.2 and stata 14.0. The heterogeneity of data will be investigated by Cochrane X and I tests. Sensitivity analysis will be conducted to evaluate the stability of the results. A funnel plot analysis and Egger's test will be drawn to assess the publication bias. Finally, we will use the Grading of Recommendations Assessment, Development and Evaluate system to evaluate the methodological quality. RESULTS: The results of our research will be published in a peer-reviewed journal. CONCLUSION: The conclusion of our systematic review will provide evidence to judge whether WFC is an effective intervention for patient with CAG. OSF REGISTRATION NUMBER: 10.17605/OSF.IO/2UTMB.